Endostatin is under clinical development by Simcere Pharmaceutical Group and currently in Phase III for Malignant Pleural Effusion. According to GlobalData, Phase III drugs for Malignant Pleural Effusion have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Endostatin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Endostatin overview

Endostatin (Endostar/ Recombinant Human Endostatin) is a angiostatic protein prepared by using recombinant DNA technology. It is formulated as injectable solution for intravenous drip route of administration. Endostar in combination with NP chemotherapy regimen is indicated for the treatment of patients with stage III/IV non-small cell lung cancer. T
Endostatin (Endostar/ Recombinant Human Endostatin) in combination with cisplatin is also under development for the treatment of malignant pleural effusion, malignant thoracoabdominal effusions, ascite, nasopharyngeal carcinoma and non-small cell lung cancer. It is administered through intravenous route. The drug candidate was under development for the treatment of peripheral T-cell lymphoma.

Simcere Pharmaceutical Group overview

Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company that discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers services in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle and others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low-end generics and APIs for innovative medicines. Simcere is headquartered in Nanjing, Jiangsu, China

For a complete picture of Endostatin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.